BACKGROUND
==========

Given the irreversible retinal ganglion cell damage resulting from open-angle glaucoma (OAG), current treatment modalities are focused on preserving the structural integrity of the optic nerve and visual function.^[@B1]-[@B3]^ Prospective evaluations in glaucoma have demonstrated that the reduction of IOP leads to significant sparing of vision: namely, every 1 mm Hg reduction of IOP is correlated with an approximate 10% decrease in the risk of glaucomatous progression.^[@B4]^

In OAG, IOP elevation is often a result of reduced aqueous humor flow through the trabecular meshwork^[@B5]^ In early stages, ocular hypotensive medications and laser trabeculoplasty have been shown to attenuate glaucoma progression; however there are well known issues with compliance, tolerability, persistence, and difficulty of proper instillation.^[@B3][@B5]^ In the situations in which these treatments are insufficient in reducing IOP to target pressures according to disease severity, ab externo filtering procedures are utilized to provide a more significant IOP reduction. Unfortunately, these techniques are higher risk options that may result in a bleb-related complication, hemorrhage, hyphema, hypotony, infection, inflammation, loss of vision or reoperation.^[@B6][@B7]^

Recently, there has been increasing interest in the ability of microinvasive glaucoma surgery (MIGS) devices to provide a significant level of IOP reduction with less severe postoperative adverse events.^[@B8]^ One such device, the iStent ® (Glaukos Corporation, San Clemente, California), is the first ab interno glaucoma implant that has been approved for the management of mild-to-moderate OAG.^[@B9]^ The iStent works by allowing aqueous humor to drain directly from the anterior chamber into Schlemm's canal, thus bypassing a portion of the trabecular meshwork and reducing IOP.^[@B10]^ Currently, the iStent has only received food and drug administration approval for use combined with cataract surgery.

Multiple randomized controlled trials and case series have investigated the efficacy and adverse event profile of the iStent device.^[@B2][@B11]-[@B37]^ Some have directly compared the combination of iStent implantation and phacoemulsification to phacoemulsification alone.^[@B3][@B16][@B17][@B19]-[@B22][@B30]^ Others have been single-armed case series or have compared the iStent to ocular hypotensive medications.^[@B11]-[@B15][@B18][@B23]-[@B29]^ More recent research has focused on a second-generation trabecular micro-bypass device termed the iStent inject,^[@B11][@B14][@B20][@B24][@B29][@B34][@B36]^ which consists of two heparin coated titanium stents that are both inserted ab interno through the trabecular mesh-work into Schlemm's canal.^[@B29]^ Differences in outcomes between single versus multiple iStents have also been investigated.^[@B11][@B13][@B14][@B17][@B20][@B21][@B23]-[@B25][@B29][@B31]^ In general, most studies have focused on patients with early stages of primary OAG ^[@B11][@B14]-[@B16][@B21][@B22][@B27]-[@B29][@B32]^

There has been a rapid expansion of iStent research in recent years.^[@B3][@B11]-[@B37]^ Given these new data, it is uncertain whether there are any differences in efficacy between single versus multiple stents or between phaco-iStent compared to either iStent alone or phacoemulsification alone. Additionally, the most frequently reported adverse events in the literature following iStent therapy should be identified. As such, the following meta-analysis aims to investigate the efficacy and adverse event profile of iStent implantation for the management of OAG.

METHODS
=======

Literature Search and Data Collection
-------------------------------------

A systematic literature search was performed on Ovid MEDLINE (2006-Week 1 2018) and Ovid EMBASE (20062018 Week 3). The search strategy that was used can be found in [Table 1A](#Table1A){ref-type="table"} and [B](#Table1B){ref-type="table"}. Further, Google, Google Scholar and the reference lists of past reviews were manually searched to elicit further relevant literature. Any original prospective or retrospective clinical study that provided relevant efficacy data (i.e., IOP and number of medication classes) on the implantation of the iStent for at least five eyes was included. Only peer-reviewed journal articles were included. Non-english studies, letters to the editor, correspondences, editorials, reviews, opinions, case reports, articles reporting on other surgical procedures and studies that contained repeat data or less than 4 week follow-up were excluded. Studies were screened first by consulting titles and abstracts and afterwards by examining full-text versions. To assist with the screening process, a quality assessment of articles was performed. The Cochrane criteria were used in the assessment of randomized controlled trials, while the National Institute for Health and Care Excellence tool was used to evaluate case series.^[@B38][@B39]^ In both cases, studies were excluded if there was a high risk of bias in at least half of the assessment categories.

###### 

**Table 1A:** Search strategy for Ovid MEDLINE

  ------ ------ ----------------------------------------- ------ ----------- ------
  *\#*          *Searches*                                       *Results*       
  *1*           iStent.m_titl.                                   29              
  2             iStent.mp.                                       62              
  3             Trabecular micro-bypass.mp.                      25              
  4             Glaukos.mp.                                      30              
  5             Microinvasive glaucoma surgery.mp.               12              
  6             Minimally invasive glaucoma surgery.mp.          38              
  7             Minimally Invasive Surgical Procedures/          24740           
  8             Ophthalmologic Surgical Procedures/              12012           
  9             7 and 8                                          86              
  10            Stents/                                          65102           
  11            Glaucoma/                                        37134           
  12            10 and 11                                        43              
  13            1 or 2 or 3 or 4 or 5 or 6 or 9 or 12            222             
  14            Limit 13 to yr = "2006-Current"                  205             
  ------ ------ ----------------------------------------- ------ ----------- ------

###### 

**Table 1B:** Search strategy for Ovid EMBASE

  ------ ------ ----------------------------------------- ------ ----------- ------
  *\#*          *Searches*                                       *Results*       
  *1*           iStent.m_titl.                                   47              
  2             iStent.mp.                                       158             
  3             Trabecular micro-bypass.mp.                      52              
  4             Glaukos.mp.                                      125             
  5             Microinvasive glaucoma surgery.mp.               27              
  6             Minimally invasive glaucoma surgery.mp.          73              
  7             Minimally invasive surgery/                      33752           
  8             Eye surgery/                                     66              
  9             1 and 8                                          66              
  10            Stent/                                           81559           
  11            Glaucoma/                                        51832           
  12            10 and 11                                        87              
  13            1 or 2 or 3 or 4 or 5 or 6 or 9 or 12            358             
  14            Limit 13 to yr = "2006-Current"                  340             
  ------ ------ ----------------------------------------- ------ ----------- ------

Variables that were included for the baseline demographic evaluation were country of origin, study design, distribution of right and left eyes, age, gender, ethnicity, cup-to-disc ratio, visual field, mean deviation and time of follow-up. The primary efficacy endpoint, IOP, was collected as a continuous variable (i.e., IOP postoperatively and reduction pre- to post-operatively). The postoperative number of hypotensive medication classes and pre- to post-operative reduction in the number of medication classes was the secondary endpoint. For the efficacy analysis, data on the number of iStents and phacoemulsification status (i.e., whether concomitant phacoemulsification was performed) were extracted. For adverse event analysis, the number of events and the four most prevalent events for each study arm were recorded. Postoperative outcomes were collected at last follow-up.

Statistical Analysis
--------------------

Weighted mean differences (WMD) and corresponding 95% confidence intervals (95% CI) were reported in the analysis of primary and secondary endpoints. Throughout the analysis, the number of eyes (i.e., sample size) was used as a weighted variable. Alongside a random effects model, the inverse variance method was used in the meta-analysis. The weighted mean was defined as

![](jocgp-12-067-i001.jpg)

while the weighted standard deviation was computed using the formula

![](jocgp-12-067-i002.jpg)

Due to the differential reporting of included studies, each unique endpoint contains data from a different collection of studies. A consequence of this is that the WMDs of IOP and medication class reduction will likely not equal the difference between the preoperative and postoperative values for IOP and medication class count.

In the test for overall effect, a p-value of less than 0.05 was considered statistically significant. The main analysis was performed based on whether patients had 1, 2 or 3 iStents implanted and whether they did or did not receive combined phacoemulsification and iStent. All statistical analyses were performed using Review Manager (RevMan 5.3; The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark) and Microsoft ® Excel (Microsoft Corporation, Redmond, Washington).

REVIEW RESULTS
==============

Study Inclusions and Baseline Demographics
------------------------------------------

The systematic search revealed 545 results. Upon title and abstract screening, the number of potential articles was reduced to 135. Afterwards, full-text screening resulted in 28 studies that met al.l inclusion criteria ([Fig. 1](#F1){ref-type="fig"}).^[@B3][@B11]-[@B37]^ Baseline characteristics and the results of quality assessment for included studies are reported on [Table 2A](#Table2A){ref-type="table"}. Within the cohort of 1773 eyes for which there was relevant demographic information, the mean age was 71.4 ± 5.4 years (n = 1606; cohort range: 54.4-78.8 years), and 747 out of 1662 eyes were male (44.9%). Most eyes came from Caucasian patients (870 out of 1089 eyes, 79.9%). Generally, studies were moderate to high quality ([Tables 2B](#Table2B){ref-type="table"} and [C](#Table2C){ref-type="table"}). No study met the a priori condition for exclusion based on the quality assessment.

![Modified preferred reporting Items for systematic reviews and meta-analysis (PRISMA) flow diagram](jocgp-12-067-g001){#F1}

Of the 1767 eyes included in the efficacy and adverse event analysis, a total of 1217 (68.9%) underwent combined iStent implantation and phacoemulsification, while 497 eyes (28.1%) underwent iStent implantation alone ([Table 3](#Table3){ref-type="table"}). More than half of included eyes had one iStent implanted (999, 56.5%), while 685 eyes had two (38.8%) and 63 eyes received three (3.6%). Overall, the vast majority of eyes (1398, 79.1%) received a first generation iStent, while only 369 eyes (20.9%) received an iStent inject. The distribution of relevant clinical features between groups is presented in [Table 4](#Table4){ref-type="table"}.

In terms of study design, the majority (19/28; 67.9%) of studies were case series, while another 17.9% (5/28) were randomized controlled trials. A total of 60.7% of studies were prospective (17/28), while the rest (11/28, 39.3%) were retrospective. Most studies (22/27; 81.5%) extracted data from a single center while a smaller number were multicentered (5/27; 18.5%).

Number of iStents-First Generation
----------------------------------

Not accounting for phacoemulsification status, meta-analysis was only possible to evaluate the effect of the number of stents on IOP and medication class reduction for first generation iStents ([Table 5A](#Table5A){ref-type="table"}-[C](#Table5C){ref-type="table"}, [Figs 2A](#F2A){ref-type="fig"} and [B](#F2B){ref-type="fig"}). When examining IOP reduction, there was a significantly greater decrease after two stents compared to one \[WMD = -1.36 mm Hg, 95% CI = (-1.92 mm Hg, -0.80 mm Hg), p \< 0.001\]. This may have been influenced by the fact that two-stent patients had a significantly greater preopera-tive IOP than one-stent patients \[WMD = -1.35 mm Hg, 95% CI = (-1.85 mm Hg, -0.85 mm Hg), p \< 0.001\]. At the same time, implantation of two stents led to a lesser postoperative IOP when compared to one \[WMD = 1.02 mm Hg, 95% CI = (0.80 mm Hg, 1.24 mm Hg), p \< 0.001\]. There was a greater IOP reduction \[WMD= -4.66 mm Hg, 95% CI = (-6.20 mm Hg, -3.12 mm Hg), p \< 0.001\], higher preoperative IOP \[WMD = -2.80 mm Hg, 95% CI = (-3.93 mm Hg, -1.67 mm Hg), p \< 0.001\] and lower postoperative IOP \[WMD = 1.57 mm Hg, 95% CI = (1.12 mm Hg, 2.02 mm Hg), p \< 0.001\] following three stents relative to one. There was a greater IOP reduction \[WMD = -3.30 mm Hg, 95% CI = (-4.93 mm Hg, -1.67 mm Hg), p \< 0.001\], higher preoperative IOP \[WMD = -1.45 mm Hg, 95% CI = (-2.65 mm Hg, -0.25 mm Hg), p = 0.02\] and a lower postoperative IOP \[WMD = 0.55 mm Hg, 95% CI =(0.06 mm Hg, 1.04 mm Hg), p = 0.03\] after three stents relative to two.

###### 

**Table 2A:** Baseline demographics of included trials

  ----------------------------------- ---- -------------------------- ---- -------------------------------- ---- ----------------------------------------- ---- -------------------------------------------------------------------- ---- ------------------ ---- --------------- ---- ------------------- ---- ------------------------ ---- -------------------------- ---- ------------------------------ ----
  *Study*                                  *Country*                       *Single center or multicenter*        *Study design*                                 *2016 journal 2-year cites per document*                                  *Number of eyes*        *Age*                *Number of males*        *Number of Caucasians*        *Mean cup-to-disk ratio*        *Mean visual field (MD, dB)*     
  Samuelson et al., 2011                   United States                   Multicenter                           Prospective randomized controlled trial        Ophthalmology; 7.40                                                       117                     74 ±8                46                       83                            n/a                             --3.75 ± 3.03                    
  Fea etal., 2014                          Europe                          Multicenter                           Prospective randomized controlled trial        Clinical ophthalmology; 1.86                                              94                      64.5 ± 10.3          37                       94                            n/a                             n/a                              
  Buchacra et al., 2011                    Spain                           Single center                         Prospective case series                        Clinical ophthalmology; 1.86                                              10                      54.4 ±7.9            9                        n/a                           n/a                             n/a                              
  Ahmed etal., 2014                        Armenia                         Single center                         Prospective case series                        Journal of Cataract and Refractive Surgery; 2.69                          39                      62.8 ± 12.6          21                       39                            0.7 ±0.1                        --6.47 ± 7.2                     
  Voskanyan et al., 2014                   Europe                          Multicenter                           Prospective case series                        Advances in therapy; 2.98                                                 99                      66.4 ± 10.9          43                       95                            0.7 ±0.2                        n/a                              
  Vandewalle et al., 2009                  Belgium                         Single center                         Prospective case series                        Bulletin de la Societe Beige d'Ophtalm ologie; 0.158 (2015)               10                      69                   n/a                      n/a                           n/a                             --13.7                           
  Fea, 2010                                Italy                           Single center                         Prospective randomized controlled trial        Journal of Cataract and Refractive Surgery; 2.69                          12                      64.5 ±3.4            4                        n/a                           n/a                             n/a                              
  Belovay etal., 2012                      Canada                          Single center                         Prospective case series                        Journal of Cataract and Refractive Surgery; 2.69                          26                      78.8 ± 7             7                        18                            0.76 ±0.16                      --12.6 ±7.1                      
  2nd study arm                            Canada                          Single center                         Prospective case series                        Journal of Cataract and Refractive Surgery; 2.69                          23                      75 ± 7.3             9                        11                            0.71 ±0.17                      .-10.2 ±8.1                      
  Patel etal., 2013                        United Kingdom                  Single center                         Prospective case series                        Clinical and Experimental Ophthalmology; 2.93                             44                      76.8                 n/a                      n/a                           n/a                             n/a                              
  Arriola- Villalobos et al., 2012)        Spain                           Single center                         Prospective case series                        British Journal of Ophthalmology; 3.52                                    19                      74.63 ± 8.44         9                        19                            n/a                             n/a                              
  Arriola-Villalobos et al., 2013          Spain                           Single center                         Prospective case series                        British Journal of Ophthalmology; 3.52                                    20                      75.1 ± 8.6           9                        20                            n/a                             n/a                              
  Fernandez-Barrientos et al., 2010        Spain                           Single center                         Prospective randomized controlled trial        Investigative Ophthalmology and Visual Science; 3.15                      17                      75.2 ±7.2            6                        n/a                           n/a                             n/a                              
  Spiegel etal., 2009                      Europe                          Multicenter                           Prospective case series                        European Journal of Ophthalmology; 1.15                                   47                      76.2 ±6.7            18                       46                            n/a                             n/a                              
  Wang etal., 2015                         Canada                          Single center                         Retrospective case series                      Journal of Ophthalmology; 1.79                                            96                      70.6 ±2.8            53                       86                            n/a                             --7.3 ±2.1                       
  Klamann etal., 2015                      Germany                         Single center                         Retrospective case series                      Graefe's Archive for Clinical and Experimental Ophthalmology; 2.42        35                      61.3 ±3.5            15                       n/a                           n/a                             n/a                              
  Khan etal., 2015                         Canada and United States        Multicenter                           Retrospective case series                      Journal of Cataract and Refractive Surgery; 2.69                          49                      77.5 ±11.9           20                       34                            n/a                             --11.5 ±8.0                      
  Seibold etal., 2016                      United States                   Single center                         Retrospective case series                      Journal of Cataract and Refractive Surgery; 2.69                          64                      73.9 ±8.8            23                       34                            n/a                             n/a                              
  Gallardo etal., 2016                     United States                   Single center                         Retrospective case series                      Clinical Ophthalmology; 1.86                                              100                     74.6 ±8.9            37                       14                            0.7 ±0.2                        n/a                              
  Ferguson et al., 2016                    United States                   Single center                         Retrospective case series                      Clinical Ophthalmology; 1.86                                              350                     74.1 ± 9.0           133                      n/a                           n/a                             n/a                              
  Lindstrom et al., 2016                   Armenia                         Single center                         Prospective case series                        Advances in Therapy; 2.98                                                 57                      65.3 ±9.0            30                       57                            0.7 ±0.1                        --4.9 ±5.3                       
  El Wardani etal., 2015                   Switzerland                     n/a                                   Retrospective case series                      Klinische Monatsblatter fur Augenheilkunde; 0.52                          31                      n/a                  n/a                      n/a                           n/a                             n/a                              
  2nd Study Arm                            Switzerland                     n/a                                   Retrospective case series                      Klinische Monatsblatter fur Augenheilkunde; 0.52                          22                      n/a                  n/a                      n/a                           n/a                             n/a                              
  Katzetal., 2015                          Armenia                         Single center                         Prospective randomized controlled trial        Clinical Ophthalmology; 1.86                                              38                      68.1 ± 9.1           27                       38                            0.68 ±0.11                      --4.72 ± 4.42                    
  2nd Study Arm                            Armenia                         Single center                         Prospective randomized controlled trial        Clinical Ophthalmology; 1.86                                              41                      67.8 ±9.3            19                       41                            0.71 ±0.14                      --5.20 ± 5.65                    
  3rd Study Arm                            Armenia                         Single center                         Prospective randomized controlled trial        Clinical Ophthalmology; 1.86                                              40                      60.9 ±8.1            19                       40                            0.70 ±0.12                      --4.81 ± 4.22                    
  Shiba etal., 2017                        Japan                           Single center                         Prospective case series                        Journal of Ophthalmology; 1.79                                            10                      64.6 ± 10.7          7                        0                             n/a                             --15.4 ±8.1                      
  Zheng etal., 2017                        USA                             Single center                         Retrospective case series                      International Journal of Ophthalmology; 1.30                              34                      74                   9 of 30                  21 of 30                      n/a                             n/a                              
  Berdahl etal., 2017                      Armenia                         Single center                         Prospective case series                        Clinical & Experimental Ophthalmology; 2.93                               53                      64.7 ±9.6            27                       53                            0.7 ±0.1                        n/a                              
  Ferguson et al., 2017                    USA                             Single center                         Retrospective case series                      Journal of Cataract and Refractive Surgery; 2.69                          115                     77.42 ±8.51          86                       n/a                           0.68 ±0.11                      n/a                              
  Gonnermann et al., 2017                  Germany                         Single center                         Retrospective case series                      Graefe's Archivefor Clinical and Experimental Ophthalmology; 2.42         27                      73.8 ±7.8            13                       27                            n/a                             n/a                              
  Kurji etal., 2017                        Canada                          Single center                         Retrospective case series                      Canadian Journal of Ophthalmology; 1.57                                   34                      75.02 ± 10.34        11                       n/a                           n/a                             n/a                              
  ----------------------------------- ---- -------------------------- ---- -------------------------------- ---- ----------------------------------------- ---- -------------------------------------------------------------------- ---- ------------------ ---- --------------- ---- ------------------- ---- ------------------------ ---- -------------------------- ---- ------------------------------ ----

\*MD = Mean deviation; dB = Decibels; n/a = Not available.

###### 

**Table 2B:** Quality assessment of included randomized controlled trials (Cochrane criteria)

  ----------------------------- ------ -------- ------ ----------------------------------------------- ------ ------------------------------------------- ------ ------------------------------------------------------------- ------ --------------------------------------------------- ------ -------------------------------------------- ------ ---------------------------------------- ------ -------------- ------
  *Study*                              *Year*          *Random sequence generation (Selection bias)*          *Allocation concealment (Selection bias)*          *Blinding of participants and personnel (Performance bias)*          *Blinding of outcome assessment (Detection bias)*          *Incomplete outcome data (Attrition bias)*          *Selective reporting (Reporting bias)*          *Other bias*       
  Samuelson et al.                     2011            Low                                                    Unclear                                            High                                                                 Low                                                        High                                                Low                                             Low                
  Fea et al.                           2014            Unclear                                                Unclear                                            High                                                                 High                                                       Low                                                 Low                                             Low                
  Fea                                  2010            Low                                                    Unclear                                            Low                                                                  Low                                                        Low                                                 Low                                             Low                
  Fernandez-Barrientos et al.          2010            Low                                                    Unclear                                            Unclear                                                              Low                                                        Low                                                 Low                                             Low                
  Katz et al.                          2015            Unclear                                                Unclear                                            High                                                                 High                                                       Low                                                 Low                                             Low                
  ----------------------------- ------ -------- ------ ----------------------------------------------- ------ ------------------------------------------- ------ ------------------------------------------------------------- ------ --------------------------------------------------- ------ -------------------------------------------- ------ ---------------------------------------- ------ -------------- ------

###### 

**Table 2C:** Quality assessment of included case series (National Institute for Health and Care Excellence Criteria)

  ---------------------------- ---- -------- ---- ------------------ ---- ----------------------------- ---- --------------------------------------------- ---- -------------------------------- ---- --------------- ---- --------------------------- ---- --------------------------------- ---- ------------------------------ ----
  *Study*                           *Year*        *Multicen-tered*        *Study objective described*        *Inclusion and exclusion criteria reported*        *Outcomes definition reported*        *Prospective*        *Consecutive recruitment*        *Description of study findings*        *Stratification of out-omes*     
  Buchacra et al.                   2011          No                      Yes                                Yes                                                No                                    Yes                  Unclear                          Yes                                    No                               
  Ahmed et al.                      2014          No                      Yes                                No                                                 Yes                                   Yes                  Unclear                          Yes                                    No                               
  Voskanyan et al.                  2014          Yes                     Yes                                Yes                                                Yes                                   Yes                  Unclear                          Yes                                    No                               
  Vandewalle et al.                 2009          No                      Yes                                Yes                                                Yes                                   Yes                  Unclear                          Yes                                    No                               
  Belovay et al.                    2012          No                      Yes                                Yes                                                No                                    Yes                  Unclear                          Yes                                    No                               
  Patel et al.                      2013          No                      Yes                                Yes                                                No                                    Yes                  Unclear                          Yes                                    No                               
  Arriola- Villalobos et al.        2012          No                      Yes                                Yes                                                No                                    Yes                  Unclear                          Yes                                    No                               
  Arriola- Villalobos et al.        2013          No                      Yes                                Yes                                                No                                    Yes                  Yes                              Yes                                    No                               
  Spigel et al.                     2009          Yes                     Yes                                Yes                                                No                                    Yes                  Unclear                          Yes                                    No                               
  Wang et al.                       2015          No                      Yes                                No                                                 Yes                                   No                   Yes                              Yes                                    Yes                              
  Klamann et al.                    2015          No                      Yes                                Yes                                                Yes                                   No                   Yes                              Yes                                    No                               
  Khan et al.                       2015          Yes                     Yes                                Yes                                                No                                    No                   Unclear                          Yes                                    Yes                              
  Seibold et al.                    2016          No                      Yes                                Yes                                                Yes                                   No                   Unclear                          Yes                                    No                               
  Gallardo et al.                   2016          No                      Yes                                Yes                                                Yes                                   No                   Yes                              Yes                                    Yes                              
  Ferguson et al.                   2016          No                      Yes                                Yes                                                Yes                                   No                   Yes                              Yes                                    Yes                              
  Lindstrom et al.                  2016          No                      Yes                                Yes                                                Yes                                   Yes                  Unclear                          Yes                                    No                               
  El Wardani et al.                 2015          No                      Yes                                Yes                                                Yes                                   No                   Yes                              Yes                                    Yes                              
  Shiba et al.                      2017          No                      Yes                                Yes                                                Yes                                   Yes                  Yes                              Yes                                    No                               
  Zheng et al.                      2017          No                      Yes                                Yes                                                No                                    No                   Unclear                          Yes                                    No                               
  Berdahl et al.                    2017          No                      Yes                                Yes                                                Yes                                   Yes                  Unclear                          Yes                                    No                               
  Ferguson et al.                   2017          No                      No                                 Yes                                                Yes                                   Yes                  Yes                              Yes                                    Yes                              
  Gonnermann et al.                 2017          No                      Yes                                Yes                                                Yes                                   No                   Unclear                          Yes                                    No                               
  Kurji et al.                      2017          No                      Yes                                Yes                                                Yes                                   No                   Yes                              Yes                                    Yes                              
  ---------------------------- ---- -------- ---- ------------------ ---- ----------------------------- ---- --------------------------------------------- ---- -------------------------------- ---- --------------- ---- --------------------------- ---- --------------------------------- ---- ------------------------------ ----

![Number of first generation iStents-IOP](jocgp-12-067-g002){#F2A}

![Number of First Generation iStents-number of medication classes](jocgp-12-067-g003){#F2B}

###### 

**Table 3:** Efficacy endpoints and stratification characteristics of included trials

  ----------------------------------- --- ------------------ --- ------------------- --- -------------------- --- ------------------------ --- ---------------------------- --- ------------------------------------------ --- ------------------------------------------ --- ---------------------- --- --------------------- --- ----------------------------------- --- --------------------- --- ----------------------------------------- ---
  *Study*                                 *Numbei of Eyes*       *IOP ' reduction*       *IOP Preoperative*       *IOP Postopera-tively*       *Reduction in medications*       *Number of Medica-tions Preopera-tively*       *Number of Medications Postopera-tively*       *Follow-up (months)*       *Number of iStents*       *Combined Phacoe-- mulsification*       *iStent Generation*       *Type of Glaucoma*                         
  Samuelson et al., 2011                  117                    8.4± 3.6                25.2 ±3.5                n/a                          1.4±0.8                          1.5 ±0.7                                       0.2±0.6                                        12                         1                         Yes                                     First                     Any                                        
  Fea et al., 2014                        94                     12.2± 2.5               25.2 ±1.4                13.0±2.3                     n/a                              1.0±0                                          n/a                                            12                         2                         No                                      Second                    Primary                                    
  Buchacra et al., 2011                   8                      6.6±5.4                 26.5± 7.9                17.0±2.5                     1.1±0.6                          2.9±0.7                                        2                                              12                         1                         No                                      First                     Secondary                                  
  Ahmed et al., 2014                      39                     13.5                    25.3 ±1.8                11.8±2.1                     1.0±0                            2.0±0                                          1.0±0                                          18                         2                         No                                      First                     Any                                        
  Voskanyan et al., 2014                  88                     10.4±3.2                26.3± 3.5                15.7±3.7                     n/a                              2.21±0.44                                      n/a                                            12                         2                         No                                      Second                    Pseudoexfol iative                         
  Vandewalle et al., 2009                 9                      4.2                     20                       15.8                         1                                2.7                                            1.7                                            12                         1                         Mixed                                   First                     Primary                                    
  Fea, 2010                               12                     3.2±3                   17.9± 2.6                14.8±1.2                     1.6                              2±0.9                                          0.4±0.7                                        15                         1                         Yes                                     First                     Primary                                    
  Belovay et al., 2012                    28                     3.5                     17.3±4                   13.8±4                       1.8                              2.8±0.8                                        1.0±1.1                                        12                         2                         Yes                                     First                     Primary, mixed                             
  2nd study arm                           25                     3.9                     18.6±4                   14.8±3                       2.2                              2.6±1.2                                        0.4±0.5                                        12                         3                         Yes                                     First                     Primary, mixed                             
  Patel et al., 2013                      44                     5                       21.5 ±5                  16.5±3                       1.7                              2.3±0.9                                        0.6±1.0                                        6                          1                         Mixed                                   First                     Any                                        
  Arriola Villalobos et al., 2012         19                     3.16±3.9                19.42±1.89               16.26±4.23                   0.47±0.96                        1.32±0.48                                      0.84±0.89                                      Mean: 53.68±9.26           1                         Yes                                     First                     Any                                        
  Arriola-Villalobos et al., 2013         20                     9.42±3                  26±3.11                  16.75±2.24                   1±0.79                           1.3±0.66                                       0.3±0.57                                       12                         1 or 2                    Yes                                     Second                    Any open angle                             
  Fernandez-Barrientos et al., 2010       17                     6.6±3.0                 24.2±1.8                 17.6±2.8                     1.1                              1.1±0.5                                        0                                              12                         2                         Yes                                     First                     Primary                                    
  Spiegel et al., 2009                    42                     4.4±4.54                21.7±3.98                17.4±2.99                    1.2±0.7                          1.6±0.8                                        0.4±0.62                                       12                         1                         Yes                                     First                     Primary                                    
  Wang et al., 2015                       96                     2.50±5.80               n/a                      n/a                          1.38±1.43                        2.14±0.16                                      0.76                                           3                          2                         Yes                                     First                     Any                                        
  Klamann et al., 2015                    32                     7.67                    22.39±1.81               14.72±0.80                   1.3                              2.26±0.1                                       0.96±0.11                                      6                          2                         No                                      Second                    Primary, pseudoexfol iative, pigmentary    
  Khan et al., 2015                       49                     n/a                     19.6±5.2                 14.3±3.1                     n/a                              2.86±0.91                                      1.22±1.28                                      12                         2                         Yes                                     First                     Primary, pseudoexfol iative, pigmentary    
  Seibold et al., 2016                    64                     1.5                     14.7±3.2                 13.2±2.8                     0.4                              1.8±1.1                                        1.4±1.5                                        12                         1                         Yes                                     First                     Any                                        
  Gallardo et al., 2016                   134                    3.6                     16.5±3.7                 12.9±2.1                     1.4                              2.3±1.1                                        0.9±1.2                                        12                         1                         Yes                                     First                     Primary                                    
  Ferguson et al., 2016                   350                    4.0                     19.1±6.3                 15.2±3.5                     0.6                              1.2±1.0                                        0.6±1.0                                        24                         1                         Yes                                     First                     Primary                                    
  Lindstrom et al., 2016                  57                     10.0                    24.4±1.3                 14.4±2.1                     1.0                              1.0±0                                          0.02                                           18                         2                         No                                      Second                    Primary                                    
  El Wardani et al., 2015                 31                     1.6                     16.7                     15.1                         1.7                              2.5                                            0.8                                            6                          1                         Yes                                     First                     N/a                                        
  2nd Study Arm                           22                     3.2                     17                       13.8                         1.1                              2.1                                            1                                              6                          2                         Yes                                     First                     N/a                                        
  Katz et al., 2015                       37                     10.6                    25.0±1.1                 14.4 ±1.2                    1.6                              1.71± 0.61                                     0.11                                           12                         1                         No                                      First                     Primary, pseudoexfol iative, pigmentary    
  2nd study arm                           41                     12.2                    25.0±1.7                 12.8 ±1.4                    1.66                             1.76±0.54                                      0.10                                           12                         2                         No                                      First                     Primary, pseudoexfol iative, pigmentary    
  3rd study arm                           38                     12.9                    25.1±1.9                 12.2 ±1.5                    1.43                             1.51± 0.69                                     0.08                                           12                         3                         No                                      First                     Primary, pseudoexfol iative, pigmentary    
  Shiba et al., 2017                      10                     5.1                     22.0±3.0                 16.9 ±3.6                    0                                3± 0                                           3±0                                            6                          2                         No                                      First                     Primary                                    
  Zheng et al., 2017                      17                     3                       19.7±4.1                 16.7 ±2.1                    1.4                              2.2± 1.2                                       0.8±1.3                                        6                          1                         Yes                                     First                     Any                                        
  Berdahl et al., 2017                    53                     6.8                     19.7±1.5                 12.9 ±2.1                    1±0                              2± 0                                           1±0                                            18                         2                         No                                      Second                    Any                                        
  Ferguson et al., 2017                   115                    5.49                    20.00 ±6.95              14.51 ±2.79                  0.7                              1.41± 1.04                                     0.71                                           24                         1                         Yes                                     First                     Pseudoexfol iative                         
  Gonnerman n et al., 2017                25                     7.8                     21.3±4.1                 0\. 13.5 ±5                  0.72                             2.0± 0.9                                       1.28±1.17                                      12                         2                         Yes                                     Second                    Primary, pseudoexfol iative                
  Kurji et al., 2017                      34                     3.87                    17.47 ±4.87              13.6 ±3.4                    0.32±0.59                        2.15± 1.21                                     1.83±1.2                                       6                          2                         yes                                     First                     Primary, pseudoexfol iative                
  ----------------------------------- --- ------------------ --- ------------------- --- -------------------- --- ------------------------ --- ---------------------------- --- ------------------------------------------ --- ------------------------------------------ --- ---------------------- --- --------------------- --- ----------------------------------- --- --------------------- --- ----------------------------------------- ---

\* IOP = intraocular pressure.

###### 

**Table 4:** Distribution of clinical features for first generation studies by type of analysis

  ------------------------------------------------------- ---- ---------------------------- ---- ---------------- ---- ---------------- ---- ------------------------------------------------------ ---- -------------------------------------------------- ----
  *Type of analysis*                                           *Baseline feature*                *Comparator 1*        *Comparator 2*        *Proportion of baseline feature in comparator 1 (%)*        *Proportion of baseline feature in comparator 2*     
  Number of iStents-reduction in IOP                           Phacoemulsification status        One iStent            Two iStents           *iStent alone:* 45/999 (4.5%)                               *iStent alone:* 90/287 (31.4%)                       
  Number of iStents-preoperative IOP                           Phacoemulsification status        One iStent            Two iStents           *iStent alone:* 45/999 (4.5%)                               *iStent alone:* 90/240 (37.5%)                       
  Number of iStents-postoperative IOP                          Phacoemulsification status        One iStent            Two iStents           *iStent alone:* 45/882 (5.1%)                               *iStent alone:* 90/240 (37.5%)                       
  Number of iStents-reduction in medications                   Phacoemulsification status        One iStent            Two iStents           *iStent alone:* 45/999 (4.5%)                               *iStent alone:* 90/287 (31.4%)                       
  Number of iStents-preoperative medications                   Phacoemulsification status        One iStent            Two iStents           *iStent alone:* 45/999 (4.5%)                               *iStent alone:* 90/336 (26.8%)                       
  Number of iStents- postoperative medications                 Phacoemulsification status        One iStent            Two iStents           *iStent alone:* 45/999 (4.5%)                               *iStent alone:* 90/336 (26.8%)                       
  Number of iStents-reduction in IOP                           Phacoemulsification status        One iStent            Three iStents         *iStent alone:* 45/999 (4.5%)                               *iStent alone:* 38/63 (60.3%)                        
  Number of iStents-preoperative IOP                           Phacoemulsification status        One iStent            Three iStents         *iStent alone:* 45/999 (4.5%)                               *iStent alone:* 38/63 (60.3%)                        
  Number of iStents-postoperative IOP                          Phacoemulsification status        One iStent            Three iStents         *iStent alone:* 45/882 (5.1%)                               *iStent alone:* 38/63 (60.3%)                        
  Number of iStents-reduction in medications                   Phacoemulsification status        One iStent            Three iStents         *iStent alone:* 45/999 (4.5%)                               *iStent alone:* 38/63 (60.3%)                        
  Number of iStents-preoperative medications                   Phacoemulsification status        One iStent            Three iStents         *iStent alone:* 45/999 (4.5%)                               *iStent alone:* 38/63 (60.3%)                        
  Number of iStents - postoperative medications                Phacoemulsification status        One iStent            Three iStents         *iStent alone:* 45/999 (4.5%)                               *iStent alone:* 38/63 (60.3%)                        
  Number of iStents -reduction in IOP                          Phacoemulsification status        Two iStents           Three iStents         *iStent alone:* 90/287 (31.4%)                              *iStent alone:* 38/63 (60.3%)                        
  Number of iStents -preoperative IOP                          Phacoemulsification status        Two iStents           Three iStents         *iStent alone:* 90/240 (37.5%)                              *iStent alone:* 38/63 (60.3%)                        
  Number of iStents -postoperative IOP                         Phacoemulsification status        Two iStents           Three iStents         *iStent alone:* 90/240 (37.5%)                              *iStent alone:* 38/63 (60.3%)                        
  Number of iStents -reduction in medications                  Phacoemulsification status        Two iStents           Three iStents         *iStent alone:* 90/287 (31.4%)                              *iStent alone:* 38/63 (60.3%)                        
  Number of iStents -preoperative medications                  Phacoemulsification status        Two iStents           Three iStents         *iStent alone:* 90/336 (26.8%)                              *iStent alone:* 38/63 (60.3%)                        
  Number of iStents - postoperative medications                Phacoemulsification status        Two iStents           Three iStents         *iStent alone:* 90/336 (26.8%)                              *iStent alone:* 38/63 (60.3%)                        
  Phacoemulsification status - IOP reduction                   Number of iStents                 iStent alone          Phaco-iStent          *One iStent:* 45/173 (26.0%)                                *One iStent:* 901/1123 (80.2%)                       
  Phacoemulsification status - preoperative IOP                Number of iStents                 iStent alone          Phaco-iStent          *One iStent:* 45/173 (26.0%)                                *One iStent:* 901/1076 (83.7%)                       
  Phacoemulsification status - postoperative IOP               Number of iStents                 iStent alone          Phaco-iStent          *One iStent:* 45/173 (26.0%)                                *One iStent:* 784/959 (81.8%)                        
  Phacoemulsification status - reduction in medications        Number of iStents                 iStent alone          Phaco-iStent          *One iStent:* 45/173 (26.0%)                                *One iStent:* 901/1123 (80.2%)                       
  Phacoemulsification status -preoperative medications         Number of iStents                 iStent alone          Phaco-iStent          *One iStent:* 45/173 (26.0%)                                *One iStent:* 901/1172 (76.9%)                       
  Phacoemulsification status -postoperative medications        Number of iStents                 iStent alone          Phaco-iStent          *One iStent:* 45/173 (26.0%)                                *One iStent:* 901/1172 (76.9%)                       
  ------------------------------------------------------- ---- ---------------------------- ---- ---------------- ---- ---------------- ---- ------------------------------------------------------ ---- -------------------------------------------------- ----

IOP = intraocular pressure.

###### 

**Table 5A:** Efficacy outcomes of one versus two first generation iStent implantation

  ---------------------------- ---- -------------- ---- ---------------------- ---- ------------------ ---- -------- ---- ---------------------- ---- ------------------ ---- ---------------------------- ---- ------------------------ ---- ------------------------- ---- ------------ ----
                                    *One iStent*        *Two iStents*               *Meta-analysis*                                                                                                                                                                                       
  *Outcome*                         *Mean*              *Standard deviation*        *Number of eyes*        *Mean*        *Standard deviation*        *Number of eyes*        *Weighted mean difference*        *95% CI - lower bound*        *95% CI -- upper bound*        *p-value*      
  IOP reduction                     4.67                2.18                        999                     6.03          4.66                        355                     --1.36                            --1.86                        --0.86                         p \<0.001      
  Preoperati ve IOP                 19.72               3.06                        999                     21.07         3.66                        240                     --1.35                            --1.85                        --0.85                         p \<0.0        
  Postopera tive IOP                14.80               1.25                        882                     13.78         1.62                        240                     1.02                              0.80                          1.24                           p \<0.001      
  Reduction in medications          0.97                0.46                        999                     1.20          0.51                        287                     --0.23                            --0.30                        --0.16                         p \<0.001      
  Preoperati ve medicatio ns        1.62                0.48                        999                     2.21          0.48                        336                     --0.59                            --0.65                        --0.53                         p \<0.0 01     
  Postopera tive medications        0.67                0.34                        999                     0.95          0.64                        336                     --0.28                            --0.35                        --0.21                         p \<0.001      
  ---------------------------- ---- -------------- ---- ---------------------- ---- ------------------ ---- -------- ---- ---------------------- ---- ------------------ ---- ---------------------------- ---- ------------------------ ---- ------------------------- ---- ------------ ----

\*IOP = Intraocular pressure. CI = Confidence interval

###### 

**Table 5B:** Efficacy outcomes of one versus three first generation iStent implantation

  ---------------------------- ---- -------------- ---- ---------------------- ---- ------------------ ---- -------- ---- ---------------------- ---- ------------------ ---- ---------------------------- ---- ----------------------- ---- ----------------------- ---- ----------- ----
                                    *One iStent*        *Three iStents*             *Meta-Analysis*                                                                                                                                                                                   
  *Outcome*                         *Mean*              *Standard deviation*        *Number of eyes*        *Mean*        *Standard deviation*        *Number of eyes*        *Weighted mean difference*        *95%CI --Lower bound*        *95%CI --Upper bound*        *p-value*     
  IOP reduction Preoperative        4.67                2.18                        999                     9.33          6.23                        63                      --4.66                            --6.20                       --3.12                       p \<0.001     
  IOP Postoperative                 19.72               3.06                        867                     22.52         4.50                        63                      --2.80                            --3.93                       --1.67                       p \<0.001     
  IOP Reduction in                  14.80               1.25                        882                     13.23         1.80                        63                      1.57                              1.12                         2.02                         p \<0.001     
  medications Preoperative          0.97                0.46                        999                     1.74          0.53                        63                      --0.77                            --0.90                       --0.64                       p \<0.001     
  medications                       1.62                0.48                        999                     1.94          0.75                        63                      --0.32                            --0.51                       --0.13                       p \<0.001     
  Postoperative medications         0.67                0.34                        999                     0.21          0.22                        63                      0.46                              0.40                         0.52                         p \<0.001     
  ---------------------------- ---- -------------- ---- ---------------------- ---- ------------------ ---- -------- ---- ---------------------- ---- ------------------ ---- ---------------------------- ---- ----------------------- ---- ----------------------- ---- ----------- ----

\*IOP = Intraocular pressure. CI = Confidence interval. n/a = Not available. Note: red text denotes endpoints that substantially differed from those of the original analysis.

###### 

**Table 5C:** Efficacy outcomes of two versus three first generation iStent implantation

  --------------------------- ---- --------------- ---- ---------------------- ---- ------------------ ---- -------- ---- ---------------------- ---- ------------------ ---- ---------------------------- ---- ----------------------- ---- ----------------------- ---- ----------- ----
                                   *Two iStents*        *Three iStents*             *Meta-Analysis*                                                                                                                                                                                   
  *Outcome*                        *Mean*               *Standard deviation*        *Number of eyes*        *Mean*        *Standard deviation*        *Number of eyes*        *Weighted mean difference*        *95%CI --Lower bound*        *95%CI --Upper bound*        *p-value*     
  IOP reduction                    6.03                 4.66                        287                     9.33          6.23                        63                      --3.30                            --4.93                       --1.67                       p \<0.001     
  Preoperative IOP                 21.07                3.66                        240                     22.52         4.50                        63                      --1.45                            --2.65                       --0.25                       p = 0.02      
  Postoperative IOP                13.78                1.62                        240                     13.23         1.80                        63                      0.55                              0.06                         1.04                         p = 0.03      
  Reduction in medications         1.20                 0.51                        287                     1.74          0.53                        63                      --0.54                            --0.68                       --0.40                       p \<0.001     
  Preoperative medications         2.21                 0.48                        336                     1.94          0.75                        63                      0.27                              0.08                         0.46                         p = 0.006     
  Postoperative medications        0.95                 0.64                        336                     0.21          0.22                        63                      0.74                              0.65                         0.83                         p \<0.001     
  --------------------------- ---- --------------- ---- ---------------------- ---- ------------------ ---- -------- ---- ---------------------- ---- ------------------ ---- ---------------------------- ---- ----------------------- ---- ----------------------- ---- ----------- ----

\*IOP = Intraocular pressure. CI = Confidence interval. n/a = Not available. Note: Red text denotes endpoints that substantially differed from those of the original analysis.

For the number of hypotensive medication classes, there was a greater reduction in medication classes following two iStents relative to one \[WMD = -0.23, 95% CI = (-0.30, -0.16), p \< 0.001\]. There was a significantly greater number of medication classes in two stent patients compared to one both preoperatively \[WMD = -0.59, 95% CI = (-0.65, -0.53), p \< 0.001\] and postoperatively \[WMD = -0.28, 95% CI = (-0.35, -0.21), p \< 0.001\]. Comparing between one and three stents, there was a significantly higher number of medication classes \[WMD = -0.32, 95%CI = (-0.51, -0.13), p \< 0.001\] in the three stent cohort preoperatively, as well as a greater reduction in medication class number \[WMD = -0.77, 95% CI = (-0.90, -0.64), p \< 0.001). Postoperatively, the three stent group had a significantly lower medication class count \[WMD = 0.46, 95% CI = (0.40, 0.52), p \< 0.001\]. There was a greater reduction in medication classes \[WMD = -0.54, 95% CI = (-0.68, -0.40), p \< 0.001\], lower preoperative \[WMD = 0.27, 95% CI = (0.08, 0.46), p = 0.006\] and lower postoperative medication class count \[WMD = 0.74, 95% CI = (0.65, 0.83), p \< 0.001\] following three stents relative to two.

Phacoemulsification Status-First Generation
-------------------------------------------

Next, studies were categorized by whether phacoemulsification was performed, irrespective of the number of first-generation iStents ([Table 6A](#Table6A){ref-type="table"}, [Figs 3A](#F3A){ref-type="fig"} and [B](#F3B){ref-type="fig"}). Data revealed that the iStent alone group produced a significantly more pronounced reduction in IOP than the phaco-iStent cohort \[WMD = -7.44 mm Hg, 95% CI = (-7.82 mm Hg, -7.06 mm Hg), p \< 0.001\]. The iStent alone group also had a significantly greater preoperative IOP than the phaco-iStent cohort \[WMD = -5.72 mm Hg, 95% CI = (-5.93 mm Hg, -5.51 mm Hg), p \< 0.001\]. Nonetheless, the iStent alone cohort had a lower postoperative IOP relative to the phaco-iStent cohort \[WMD = 1.42 mm Hg, 95% CI = (1.15 mm Hg, 1.69 mm Hg), p \< 0.001\].

###### 

**Table 6A:** First Generation iStent - Efficacy Outcomes of Phaco-iStent versus iStent Implantation Alone

  ---------------------------- ---- ---------------- ---- ----------------------------- ---- ------------------ ---- -------- ---- ---------------------- ---- ------------------ ---- ---------------------------- ---- ------------------------ ---- ------------------------ ---- ----------- ----
                                    *Phaco-istent*        *Istent implantation alone*        *Meta-analysis*                                                                                                                                                                                     
  *Outcome*                         *Mean*                *Standard deviation*               *Number of eyes*        *Mean*        *Standard deviation*        *Number of eyes*        *Weighted mean difference*        *95% CI --Lower bound*        *95% CI --Upper bound*        *P-value*     
  IOP reduction Preoperative        4.20                  1.82                               1123                    11.64         2.47                        173                     --7.44                            --7.82                        --7.06                        p \<0.001     
  IOP Postoperative                 19.27                 2.78                               1076                    24.99         0.88                        173                     --5.72                            --5.93                        --5.51                        p \<0.001     
  IOP Reduction in                  14.64                 1.21                               959                     13.22         1.72                        173                     1.42                              1.15                          1.69                          p \<0.001     
  medications                       0.99                  0.49                               1123                    1.33          0.46                        173                     --0.34                            --0.41                        --0.27                        p \<0.001     
  Preoperative medications          1.62                  0.60                               1172                    1.87          0.44                        173                     --0.25                            --0.32                        --0.18                        p \<0.001     
  Postoperative medications         0.73                  0.36                               1172                    0.55          0.87                        173                     0.18                              0.05                          0.31                          p = 0.007     
  ---------------------------- ---- ---------------- ---- ----------------------------- ---- ------------------ ---- -------- ---- ---------------------- ---- ------------------ ---- ---------------------------- ---- ------------------------ ---- ------------------------ ---- ----------- ----

\*IOP = Intraocular pressure. CI = Confidence interval. Note: Red text denotes endpoints that substantially differed from those of the original analysis.

Preoperatively, patients receiving combined phaco-iStent were taking significantly fewer medication classes relative to the iStent alone group \[WMD = -0.25 mm Hg, 95% CI = (-0.32 mm Hg, -0.18 mm Hg), p \< 0.001\]. There was a significantly greater reduction in medication class number following iStent alone \[WMD=-0.34mmHg, 95% CI = (-0.41 mm Hg, -0.27 mm Hg), p \< 0.001\] along with a significantly lower postoperative medication class number in the iStent alone arm relative to phaco-iStent \[WMD = 0.18 mm Hg, 95% CI = (0.05 mm Hg, 0.31 mm Hg), p = 0.007\].

The combination of phacoemulsification and a first generation iStent was also compared to phacoemulsification alone ([Table 6B](#Table6B){ref-type="table"}, [Figs 4A](#F4A){ref-type="fig"} and [B](#F4B){ref-type="fig"}). This comparison only included studies that contained both a phaco-iStent arm and a phacoemulsification alone arm. For this analysis, there was a significantly greater IOP reduction \[WMD = 1.68 mm Hg, 95% CI = (1.11 mm Hg, 2.25 mm Hg), p \< 0.001\] and a higher preoperative IOP \[WMD = 2.15 mm Hg, 95% CI = (1.35 mm Hg, 2.95 mm Hg), p \< 0.001\] following phaco-iStent relative to phacoemulsification alone. However, there was no significant difference between comparators for postoperative IOP (p = 0.07). Phaco-iStent resulted in a significantly more pronounced reduction in medication class number \[WMD = 0.80 mm Hg, 95% CI = (0.75 mm Hg, 0.85 mm Hg), p \< 0.001\] and lower postoperative number of medication classes \[WMD = -0.69 mm Hg, 95% CI = (-0.78 mm Hg, -0.60 mm Hg), p \< 0.001\] relative to phacoemulsification alone. Preoperatively, there was no significant difference between comparators (p = 0.78).

Phacoemulsification Status-Second Generation
--------------------------------------------

For the second generation iStent *inject,* studies reporting on iStent alone had a significantly greater IOP reduction \[WMD = -1.47 mm Hg, 95% CI = (-1.88 mm Hg, -1.06 mm Hg), p \< 0.001\] and a greater preoperative IOP \[WMD = -0.79 mm Hg, 95% CI = (-1.54 mm Hg, -0.04 mm Hg), p = 0.04\] compared to studies reporting on phaco-iStent ([Table 7](#Table7){ref-type="table"}, [Fig. 5A](#F5A){ref-type="fig"}). Postoperatively, the phaco-iStent cohort had a significantly higher IOP relative to iStent alone \[WMD = 0.81 mm Hg, 95% CI = (0.13 mm Hg, 1.49 mm Hg), p \< 0.001\]. There was a significantly greater reduction in medication classes \[WMD=-0.22, 95% CI = (-0.28, -0.16), p \< 0.001\], higher number of pre-operative medication classes \[WMD = 0.20, 95% CI = (0.04, 0.36), p = 0.01\] and a lower number of postoperative medication classes \[WMD = 0.24, 95% CI = (0.02, 0.46), p = 0.03\] following iStent alone relative to phaco-iStent ([Fig. 5B](#F5B){ref-type="fig"}).

###### 

**Table 6B:** First Generation iStent-Efficacy Outcomes of Phaco-iStent versus Phacoemulsification Alone

  --------------------------- ---- ---------------- ---- ----------------------------- ---- ----------------- ---- ----------- ---- ---------------------- ---- ------------------ ---- ---------------------------- ---- ----------------------- ---- ----------------------- ---- ----------- ----
                                   *Phaco-istent*        *Phacoemulsification alone*        *Meta-analysis*                                                                                                                                                                                     
  *Outcome*                        *Mean*                *Standard deviation*               *Number eyes*          *of Mean*        *Standard deviation*        *Number of eyes*        *Weighted mean difference*        *95%Ci --Lower bound*        *95%Ci --Upper bound*        *P-value*     
  IOP reduction                    6.30                  3.10                               199                    4.62             3.47                        319                     1.68                              1.11                         2.25                         p \<0.001     
  Preoperative IOP                 22.44                 4.24                               199                    20.29            4.93                        319                     2.15                              1.35                         2.95                         p \<0.001     
  Postoperative IOP                15.23                 1.53                               82                     14.84            1.80                        196                     0.39                              --0.03                       0.81                         p = 0.07      
  Reduction in medications         1.40                  0.21                               199                    0.60             0.36                        319                     0.80                              0.75                         0.85                         p \<0.001     
  Preoperative medications         1.72                  0.47                               199                    1.71             0.25                        319                     0.01                              --0.06                       0.08                         p = 0.78      
  Postoperative medications        0.38                  0.36                               199                    1.07             0.63                        319                     --0.69                            --0.78                       --0.60                       p \<0.001     
  --------------------------- ---- ---------------- ---- ----------------------------- ---- ----------------- ---- ----------- ---- ---------------------- ---- ------------------ ---- ---------------------------- ---- ----------------------- ---- ----------------------- ---- ----------- ----

\*IOP = Itraocular pressure. CI = Confidence interval. Note: Red text denotes endpoints that substantially differed from those of the original analysis.
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Adverse Event Analysis
----------------------

Overall, a total of 261 out of 1159 eyes (22.5%) that received iStent implantation sustained some type of adverse event ([Table 8](#Table8){ref-type="table"}). In order from most to least common, the following adverse events were reported: IOP elevation or spike (reported in 12 of 27 papers; 44.4%), stent blockage or obstruction (8/27; 29.6%), stent malposition (7/27; 25.9%), hyphema (6/27; 22.2%), progression of cataract (3/27; 11.1%), blood reflux (3/27; 11.1%), corneal event (3/27; 11.1%), early postoperative event (2/27; 7.4%), stent not visible (2/27; 7.4%), formation of peripheral anterior synechiae (2/27; 7.4%), need for additional surgery (2/27, 7.4%), hypotony (1/27; 3.7%), posterior capsular opacification (1/27; 3.7%), replacement applicator (1/27; 3.7%), patients soreness/discomfort (1/27; 3.7%), transient visual acuity loss (1/27; 3.7%), intraoperative hemorrhage (1/27; 3.7%) and subconjunctival hemorrhage (1/27, 3.7%). Most studies reported either stable or improved visual acuity at last follow-up.

DISCUSSION
==========

The efficacy and adverse event profile of the iStent device have been explored in a variety of different settings. To evaluate the efficacy and adverse events following iStent implantation based on the consolidation of all peer-reviewed research on the iStent, the present meta-analysis was undertaken.

![Second generation phaco-iStent versus iStent alone-IOP](jocgp-12-067-g008){#F5A}
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In a recent meta-analysis by Malvankar-Mehta et al., the efficacy of the iStent without adjunctive phacoemulsification was analyzed in 248 patients from five studies.^[@B40]^ Meta-analysis revealed a significant reduction in IOP after implantation of one \[standardized mean difference (SMD) = -1.68, 95% CI = (-2.7, -0.61)\], two \[SMD = -1.88, 95% CI = (-2.2, -1.56)\] and three iStents \[SMD = -2, 95%CI = (-2.62, -1.38)\]. Glaucoma medication class number was reduced by a mean of 1.2 bottles after one iStent implant, 1.45 bottles after two iStents and one bottle after three iStents.

Another meta-analysis by the same team aimed to investigate the reduction of IOP after phaco-iStent compared to phacoemulsification alone.^[@B41]^ A total of 396 patients from 10 studies received phaco-iStent and 1768 patients from 26 studies received phacoemulsification alone. Phaco-iStent produced a significantly greater reduction in IOP relative to cataract extraction alone \[SMD = -0.46, 95%CI = (-0.87, -0.06)\]. Relative to phacoemulsification alone, phaco-iStent demonstrated a statistically significantly greater reduction in glaucoma medication class number \[SMD = -0.65, 95% CI = (-1.18, -0.12)\]. Relative to the two studies by Malvankar-Mehta and colleagues, 20 of our 28 included peer reviewed articles have not been reported in previous meta-analyses.^[@B40][@B41]^

The greater IOP reduction with multiple iStents compared to one has been documented in previous laboratory studies and was also confirmed by the findings of the present meta-analysis.^[@B42]^ For instance, both postoperative IOP and IOP reduction were significantly improved in the two-stent comparator relative to one. We hypothesize that a selection bias may have influenced these findings, as the higher initial IOP or more severe disease seen in the two-stent comparator may have contributed to the greater IOP reduction following stent implantation. For patients with high preoperative IOP (average of 22.5 mm Hg), three stents provided a more pronounced level of

###### 

**Table 7:** Second generation iStent - efficacy outcomes of phaco-iStent versus iStent implantation alone

  --------------------------- ---- ---------------- ---- ------------------------------ ---- ------------------ ---- -------- ---- ---------------------- ---- ------------------ ---- ---------------------------- ---- ------------------------ ---- ------------------------ ---- ----------- ----
                                   *Phaco-iStent*        *iStent i mplantation Alone*        *Meta-analysis*                                                                                                                                                                                     
  *Outcome*                        *Mean*                *Standard deviation*                *Number of eyes*        *Mean*        *Standard deviation*        *Number of eyes*        *Weighted mean difference*        *95% CI --Lower bound*        *95% CI-- Upper bound*        *p-value*     
  IOP reduction                    8.52                  1.14                                45                      9.99          2.14                        324                     --1.47                            --1.88                        --1.06                        p \<0.001     
  Preoperative IOP                 23.39                 2.39                                45                      24.18         2.53                        324                     --0.79                            --1.54                        --0.04                        p = 0.04      
  Postoperative IOP                14.94                 2.28                                45                      14.13         1.29                        324                     0.81                              0.13                          1.49                          p = 0.02      
  Reduction in medications         0.84                  0.20                                45                      1.06          0.16                        142                     --0.22                            --0.28                        --0.16                        p \<0.001     
  Preoperative medications         1.69                  0.49                                45                      1.49          0.64                        324                     0.20                              0.04                          0.36                          p = 0.01      
  Postoperative medications        0.84                  0.69                                45                      0.60          0.58                        142                     0.24                              0.02                          0.46                          p = 0.03      
  --------------------------- ---- ---------------- ---- ------------------------------ ---- ------------------ ---- -------- ---- ---------------------- ---- ------------------ ---- ---------------------------- ---- ------------------------ ---- ------------------------ ---- ----------- ----

\*IOP = Intraocular pressure. CI = Confidence interval.

###### 

**Table 8:** Safety endpoints of included trials

  ----------------------------------- ---- ----------------- ---- ------------------- ---- ----------------------------------------- ---- ------------------------- ---- ----------------------------------- ---- ------------------------------- ---- ------------------------------------------------------------------------------------------------------------ ----
  *Study*                                  *Number ofeyes*        *Complications*          *Adverse event 1*                              *Adverse event 2*              *Adverse event 3*                        *Adverse event 4*                    *Visual acuity change*                                                                                         
  Samuelson et al., 2011                   111                    37                       Anticipated early postoperative event          Stent obstruction              Posterior capsular opacification         Stent malposition                    97% BCVA improvement                                                                                           
  Fea et al., 2014                         94                     3                        IOP elevation                                  Soreness/ discomfort           Stent not visible                        n/a                                  Five people experienced decrease                                                                               
  Buchacra et al., 2011                    8                      17                       Hyphema                                        IOP elevation                  Corneal edema                            n/a                                  No significant change                                                                                          
  Ahmed et al., 2014                       39                     7                        Hypotony                                       Progression of cataract        Transient visual acuity loss             n/a                                  CDVA maintained in most eyes                                                                                   
  Voskanyan et al., 2014                   88                     18                       IOP elevation                                  Stent obstruction              Progression of cataract                  Stent not visible                    Slight improvement                                                                                             
  Vandewalle et al., 2009                  9                      10                       IOP elevation                                  Stent malposition              Corneal Erosion                          Blood reflux                         Stable/improved                                                                                                
  Fea, 2010                                12                     n/a                      n/a                                            n/a                            n/a                                      n/a                                  n/a                                                                                                            
  Belovay et al., 2012                     28                     n/a                      Stent blockage                                 Hyphema                        Stent malposition                        IOP elevation                        Stable/improved                                                                                                
  2nd study arm                            25                     n/a                      Stent blockage                                 Hyphema                        Stent Malposition                        IOP elevation                        Stable/improved                                                                                                
  Patel et al., 2013                       44                     1                        Hyphema                                        n/a                            n/a                                      n/a                                  Mean improved                                                                                                  
  Arriola-villalobos et al., 2012          19                     12                       Stent malposition                              Stent blockage                 Replacement applicator                   IOP elevation                        Significantly improved                                                                                         
  Arriola-villalobos et al., 2013          20                     10                       Stent malposition                              Stent blockage                 Iop elevation                            n/a                                  Significantly improved                                                                                         
  Fernandez-barrientos et al., 2010        17                     n/a                      Stent malposition                              n/a                            n/a                                      n/a                                  n/a                                                                                                            
  Spiegel et al., 2009                     42                     22                       Stent blockage                                 Stent malposition              Iop elevation                            Cataract surgery Complication        Significantly improved                                                                                         
  Wang et al., 2015                        96                     0                        n/a                                            n/a                            n/a                                      n/a                                  n/a                                                                                                            
  Klamann et al., 2015                     32                     32                       Blood reflux                                   n/a                            n/a                                      n/a                                  No decrease                                                                                                    
  Khan et al., 2015                        49                     26                       Peripheral anterior synechiae formation        IOP spike                      Early postoperative interventions        Hyphema                              n/a                                                                                                            
  Seibold et al., 2016                     64                     n/a                      n/a                                            n/a                            n/a                                      n/a                                  Significant improvement                                                                                        
  Gallardo et al., 2016                    134                    0                        n/a                                            n/a                            n/a                                      n/a                                  83% of eyes achieved a BCVA of 20/40 or better after surgery relative to 20% preoperatively                    
  Ferguson et al., 2016                    350                    n/a                      IOP spike                                      n/a                            n/a                                      n/a                                  n/a                                                                                                            
  Lindstrom et al.                         57                     1                        Progression of cataract                        n/a                            n/a                                      n/a                                  Stable                                                                                                         
  El wardani et al.                        31                     n/a                      n/a                                            n/a                            n/a                                      n/a                                  n/a                                                                                                            
  2nd study arm                            22                     n/a                      n/a                                            n/a                            n/a                                      n/a                                  n/a                                                                                                            
  Katz et al.                              37                     0                        n/a                                            n/a                            n/a                                      n/a                                  76% of eyes achieved a BCVA of 20/40 or better after surgery relative to 68%                                   
  2nd study arm                            41                     0                        n/a                                            n/a                            n/a                                      n/a                                  Preoperatively 66% of eyes achieved a BCVA of 20/40 or better after surgery relative to 61%                    
  3rd study arm                            38                     0                        n/a                                            n/a                            n/a                                      n/a                                  Preoperatively 80% of eyes achieved a BCVA of 20/40 or better after surgery relative to 73% preoperatively     
  Shiba et al., 2017                       12                     Hyphema                  Peripheral anterior synechiae                  Occlusion by iris              Iop spike                                n/a                                  n/a                                                                                                            
  Berdahl et al, 2017                      n/a                    n/a                      n/a                                            n/a                            n/a                                      n/a                                  Stable                                                                                                         
  Ferguson et al., 2017                    8                      Iop spike                Need for additional surgery                    n/a                            n/a                                      n/a                                  n/a                                                                                                            
  Gonnermann ~et~ ~al~ ~2017~              29                     Reflux ~bleeding~        Trabulectomy                                   n/a                            n/a                                      n/a                                  n/a                                                                                                            
  Kurji et al., 2017                       3                      Blocked istent           n/a                                            n/a                            n/a                                      n/a                                  Approximate 2 line gain on snellen chart                                                                       
  ----------------------------------- ---- ----------------- ---- ------------------- ---- ----------------------------------------- ---- ------------------------- ---- ----------------------------------- ---- ------------------------------- ---- ------------------------------------------------------------------------------------------------------------ ----

\* BCVA = Best corrected visual acuity; CDVA = Corrected distance visual acuity; IOP = Intraocular pressure.

IOP reduction (9.3 mm Hg) relative to one or two stents. However, interpretations of the three-stent data should be made with caution, as data from only 63 eyes existed for this comparison.

Regardless of the number of implanted iStents, the cohort that underwent first-generation iStent implantation alone saw a more pronounced IOP reduction and lower postoperative IOP than the phaco-iStent group. However, this comparison considers two different patient populations, namely (1) patients receiving iStent alone, who normally do not have cataracts and are receiving the device specifically for IOP reduction, and (2) patients undergoing combined phacoemulsification and iStent, who are receiving the treatment for both their cataracts and an elevated IOP. As such, the finding of a higher preoperative IOP in the iStent alone group may have influenced the difference in IOP reduction between comparators. Even though some included studies contained both patients who received phaco-iStent and iStent alone, subgroup analysis analyzing the differences in outcomes between these two groups was never performed in individual studies.^[@B15][@B18]^ As such, the conclusions derived from comparing phaco-iStent versus iStent alone have not been previously established.

Analysis of phaco-iStent compared to phacoemul-sification alone revealed that there was a greater IOP reduction following phaco-iStent relative to phaco-emulsification alone. This aligns with the findings of Malvankar-Mehta et al., who also showed that there was a significantly greater IOP reduction following phaco-iStent relative to phacoemulsification alone \[SMD = -0.46, 95% CI = (0.87, -0.06)\].^[@B41]^ Despite the similarity, it is important to note that uncontrolled, one-armed studies examining the efficacy of phacoemulsification alone were included in the previous analysis but were excluded in the present article.^[@B41]^ Instead, we limited our analysis of phaco-iStent versus phacoemulsification only to the studies that had a phaco-iStent arm and a phacoemulsification only comparator, thus resulting in a more controlled analysis. Beyond analysis of IOP, both meta-analyses concluded that phaco-iStent was statistically superior relative to phacoemulsification alone in the reduction of medication class number pre- to post-operatively.

The adverse event analysis revealed that fewer than 25% of eyes carried some type of adverse event postoperatively, most of which were not serious nor visually threatening. This compares favorably with the postoperative adverse event rates of both trabeculec-tomy and the Baerveldt glaucoma implant.^[@B43]^ However, due to differential reporting of adverse events between individual studies, caution should be used when interpreting these findings. In our cohort, IOP elevation, stent blockage or obstruction, stent malposition and hyphema were the most common adverse events following iStent implantation.

Beyond the efficacy and adverse event profile, the cost-effectiveness of the iStent relative to topical glaucoma medications has been studied by Iordanous and colleagues.^[@B44]^ Following implantation of two iStents, the authors analyzed cost differences at 6 years postop-eratively. At 6 years, the iStent was \$20.77 more expensive relative to monodrug therapy but was cheaper by \$1272.55 compared to bidrug treatment and \$2124.71 versus tridrug therapy. The authors concluded that the iStent may offer a modest cost saving when compared to glaucoma medications.

Given that past meta-analyses included lower numbers of eyes receiving iStent implantation (first article: 5 studies, n = 248; second article: 10 studies, n = 396), the present work (28 studies, n = 1767) represents the largest quantitative synthesis of efficacy and adverse event data for the iStent device.^[@B40][@B41]^ The large statistical power provided by such a high sample size allowed us to conduct certain analyses that were novel to the published literature; for example, an analysis comparing phaco-iStent to iStent alone. We only included published articles, thus ensuring that the rigors of peer-review were met for each included study.

Limitations of the analysis include the fact that there was no restriction of studies based on design. As such, baseline values for included endpoints were significantly different between comparator arms. As shown in [Table 4](#Table4){ref-type="table"}, the relevant clinical features were often not balanced between groups. As noted by Kaplowitz et al., variation in study design and implementation such as length of follow-up, etiology of disease and baseline clinical indicators may account for the high degree of heterogeneity upon meta-analysis.^[@B45]^ Further, since some articles did not include sociodemographic and clinical characteristics of their study cohorts (e.g. surgeon experience), it is uncertain whether there was a balance of these factors between comparator arms. For instance, there

is variable reporting of surgeon experience in the literature: two articles^[@B19][@B20]^ noted that the study surgeon was in an early stage in the learning curve, one noted that the data incorporate the surgeon learning curve,^[@B3]^ and another hypothesized how the learning curve influenced the greater number of adverse events in an initial set of patients.^[@B22]^ Two studies reported that their surgeons were experienced,^[@B24][@B30]^ while another found no significant difference in outcomes between initial and late procedures.^[@B28]^ Another limitation was that the lack of available studies prevented us from performing a robust meta-analysis for some endpoints, such as IOP reduction following three stents, where there was only 63 included patients. Limited reporting of adverse event severity across studies prevented us from analyzing severity in the adverse event analysis. Studies were variable in how they handled medication washout before stent implantation, which made it impossible to analyze the effect of preoperative medications on baseline IOP. Given that data was extracted from study cohorts, conclusions should be limited to the level of the cohort.

CONCLUSION AND CLINICAL SIGNIFICANCE
====================================

The following meta-analysis has shown that there may be differences in treatment response for the iStent due to varying parameters, including the number of iStents and phaco-iStent compared to either iStent alone or phaco-emulsification alone. In our analysis, two stents delivered a greater response in terms of IOP reduction relative to one and iStent alone had a significantly greater IOP reduction compared to phaco-iStent. Combined phaco-iStent was statistically superior relative to phacoemulsification alone in the reduction of IOP and medication classes pre-to post-operatively. Future research should determine whether similar conclusions are reached following meta-analysis in a more controlled environment.
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